Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Rhea-AI Summary

Rain Oncology Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on February 8, 2023, at 9:35 a.m. ET, in New York, NY. The discussion will provide insights into the company's leading product candidate, milademetan, an oral small molecule inhibitor targeting the p53-MDM2 complex, which reactivates p53. A live webcast of the event can be accessed here. A replay will be available on the company's website.

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Wednesday, February 8, 2023, at 9:35 a.m. ET, being held in New York, NY.

A live webcast of the fireside chat can be accessed here. A replay of the event will be available on the “Events” section of the Rain website after the conclusion of the event and will be archived on the Rain website at www.rainoncology.com.

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com        

FAQ

What is the date and time of the Rain Oncology fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference?

The fireside chat will take place on February 8, 2023, at 9:35 a.m. ET.

Who will represent Rain Oncology at the upcoming Guggenheim Healthcare Talks event?

CEO Avanish Vellanki will participate in the fireside chat.

What is milademetan, the lead candidate of Rain Oncology?

Milademetan is an oral small molecule inhibitor of the p53-MDM2 complex that reactivates p53.

How can I access the webcast of the Rain Oncology fireside chat?

The live webcast can be accessed through the link provided in the press release.

Will there be a replay of the Rain Oncology fireside chat available?

Yes, a replay will be available in the 'Events' section of Rain's website after the event.